Dainippon Sumitomo Receives Approval For Schizophrenia Drug Lonasen
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo received approval for the schizophrenia drug Lonasen (blonanserin) from Japan's Ministry of Health, Labor and Welfare and will launch the product in April 2008. The drug reduces first-stage symptoms such as flashbacks, delusions, and low stamina, and has no weight increase side effects. The Japanese schizophrenia drug market has been rapidly growing; from ¥50 billion in 2000 to ¥100 billion today. (Click here for more-Japanese language